Published in Methods Mol Biol on January 01, 2011
Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine (Lond) (2014) 0.89
Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro. Int J Nanomedicine (2014) 0.88
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomedicine (2015) 0.80
Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks. AAPS J (2014) 0.76
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Nanoparticles and the immune system. Endocrinology (2009) 1.79
Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) (2007) 1.62
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb) (2013) 1.30
Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat Protoc (2011) 1.27
Identification and avoidance of potential artifacts and misinterpretations in nanomaterial ecotoxicity measurements. Environ Sci Technol (2014) 0.95
Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Methods Mol Biol (2011) 0.92
Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine (Lond) (2013) 0.90
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) (2011) 0.89
Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. ACS Nano (2014) 0.88
Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) (2011) 0.87
Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine (Lond) (2013) 0.82
Quantitative characterization of quantum dot-labeled lambda phage for Escherichia coli detection. Biotechnol Bioeng (2009) 0.82
Qualitative analysis of total complement activation by nanoparticles. Methods Mol Biol (2011) 0.81
Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett (2013) 0.80
Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond) (2013) 0.80
Gold nanoparticle quantitation via fluorescence in solution and cell culture. Methods Mol Biol (2011) 0.79
Method for analysis of nanoparticle hemolytic properties in vitro. Methods Mol Biol (2011) 0.77
Detecting reactive oxygen species in primary hepatocytes treated with nanoparticles. Methods Mol Biol (2011) 0.76
Method for in vitro analysis of nanoparticle thrombogenic properties. Methods Mol Biol (2011) 0.76
A novel cell-based system for the rapid quantitative evaluation of (anti)-inflammatory potential of test substances. J Immunol Methods (2003) 0.75
Analysis of microbial contamination in nanoparticle formulations. Methods Mol Biol (2011) 0.75
Application of a Scavenger Receptor A1 Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV. Mol Pharm (2020) 0.75
Method for analysis of nanoparticle effects on cellular chemotaxis. Methods Mol Biol (2011) 0.75